Update on Immunotherapeutic Strategies for Recurrent and Metastatic Cervical Cancer

There are an estimated 13,800 new cases of cervical cancer in the United States each year, and 4,290 people die of the disease (ACS, 2020). Deaths have declined during the past few decades due to screening and heightened awareness, yet this malignancy continues to be a global health concern and is considered an epidemic in parts of the world. A significant proportion of patients develop advanced disease, which is rarely curable with available therapies, and treatment is often limited to palliati...
Continue reading

Image Guided Intensity Modulated Radiotherapy Reduces Bowel Toxicity in Cervical Cancer

A recent phase 3 study presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) 2020 Annual Meeting found that patients with cervical cancer undergoing postoperative adjuvant conventional radiation are more likely to develop late bowel toxicity than those undergoing image guided intensity modulated radiotherapy (IG-IMRT). For this study, results of which are published in the International Journal of Radiation Oncology, Biology, Physics, 300 patients aged 18 to 65 years ol...
Continue reading

Cancer Overscreening High Among Older Adults

Overscreening for colorectal, cervical, and breast cancer is prevalent among older adults in the United States, according to the results of a new study. While routine cancer screening for adults with average cancer risk is recommended by the US Preventive Services Task Force (USPSTF), it is recommended that screening be discontinued once individuals reach a specified upper age limit, defined as age 75 for colorectal cancer, age 65 for cervical cancer, and age 74 for breast cancer. However, many ...
Continue reading

Learning Needs: Checkpoint Inhibitors in Cervical Cancer

Pre-activity assessment data from i3 Health's continuing medical education (CME)/continuing nursing education (CNE) activity "Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy" has revealed significant baseline knowledge gaps in the area of checkpoint inhibitor therapies for advanced cervical cancer. Three hundred and ninety-seven learners took part in the educational activity and completed the pre-activity assessment, and 375 of these finished the activity ...
Continue reading

Immuno-Oncology and Checkpoint Inhibition in Cervical Cancer: Bradley Monk, MD, FACS, and Ramez Eskander, MD

​Unlike that of other gynecological malignancies, the etiology of cervical cancer is the human papillomavirus (HPV). This fact plays a role in how cervical cancer is perceived as immunogenic: T cells themselves are involved in the immune response and in the control of viral infections and the development of these tumors. In this discussion with i3 Health, Bradley Monk, MD, FACS, FACOG, Professor of Gynecologic Oncology at the University of Arizona and Creighton University, and Ramez Eskander, MD...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.